These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 17703527

  • 21. Biennial [corrected] IV zoledronic acid (Reclast) for prevention of osteoporosis.
    Med Lett Drugs Ther; 2009 Jun 29; 51(1315):49. PubMed ID: 19556940
    [No Abstract] [Full Text] [Related]

  • 22. Cost-minimization study comparing annual infusion of zoledronic acid or weekly oral alendronate in women with low bone mineral density.
    Chávez-Valencia V, Arce-Salinas CA, Espinosa-Ortega F.
    J Clin Densitom; 2014 Jun 29; 17(4):484-9. PubMed ID: 24613450
    [Abstract] [Full Text] [Related]

  • 23. [Substance properties of zoledronate make it possible: bisphosphonate therapy only once yearly].
    MMW Fortschr Med; 2006 Jun 22; 148(25):60-1. PubMed ID: 16859169
    [No Abstract] [Full Text] [Related]

  • 24. Intravenous zoledronic acid in postmenopausal women with low bone mineral density.
    Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer JP, Kaufman JM, Jaeger P, Body JJ, Brandi ML, Broell J, Di Micco R, Genazzani AR, Felsenberg D, Happ J, Hooper MJ, Ittner J, Leb G, Mallmin H, Murray T, Ortolani S, Rubinacci A, Saaf M, Samsioe G, Verbruggen L, Meunier PJ.
    N Engl J Med; 2002 Feb 28; 346(9):653-61. PubMed ID: 11870242
    [Abstract] [Full Text] [Related]

  • 25. Acute blepharitis: an unusual complication of zoledronic acid.
    Osta LE, Osta BE.
    Int J Rheum Dis; 2017 Apr 28; 20(4):515-518. PubMed ID: 26412501
    [No Abstract] [Full Text] [Related]

  • 26. [Fracture prevention in postmenopausal women with osteoporosis by an annual infusion of zoledronic acid].
    Geusens PP, Lems WF.
    Ned Tijdschr Geneeskd; 2007 Jun 30; 151(26):1445-8. PubMed ID: 17633971
    [Abstract] [Full Text] [Related]

  • 27. Vitamin D reduces musculoskeletal pain after infusion of zoledronic acid for postmenopausal osteoporosis.
    Catalano A, Morabito N, Atteritano M, Basile G, Cucinotta D, Lasco A.
    Calcif Tissue Int; 2012 Apr 30; 90(4):279-85. PubMed ID: 22350110
    [Abstract] [Full Text] [Related]

  • 28. [Zoledronic acid for preventing fractures. HORIZON trial (Health Outcomes and Reduced Incidence with Zoledronic acid ONce yearly)].
    Ringe JD, Nitschmann S.
    Internist (Berl); 2008 Apr 30; 49(4):502-4. PubMed ID: 18305914
    [No Abstract] [Full Text] [Related]

  • 29. In postmenopausal women with osteoporosis, is zoledronic acid (Reclast) superior in improving T-scores and decreasing fracture rates when compared with placebo?
    Bilbao J, Pugh A, Aspy CB.
    J Okla State Med Assoc; 2010 Aug 30; 103(8):374-5. PubMed ID: 21049709
    [No Abstract] [Full Text] [Related]

  • 30. Bisphosphonate-related osteonecrosis of jaws in 3 osteoporotic patients with history of oral bisphosphonate use treated with single yearly zoledronic acid infusion.
    Fitzpatrick SG, Stavropoulos MF, Bowers LM, Neuman AN, Hinkson DW, Green JG, Bhattacharyya I, Cohen DM.
    J Oral Maxillofac Surg; 2012 Feb 30; 70(2):325-30. PubMed ID: 21723015
    [No Abstract] [Full Text] [Related]

  • 31. [Once-yearly administration of zoledronic acid to treat post-menopausal osteoporosis].
    Seitz S, Schieker M, Mutschler W.
    Unfallchirurg; 2009 Mar 30; 112(3):346-8. PubMed ID: 19240992
    [No Abstract] [Full Text] [Related]

  • 32. Bone health medications: research questions versus clinical choices.
    Goldstein SR.
    Menopause; 2011 Aug 30; 18(8):835-6. PubMed ID: 21785375
    [No Abstract] [Full Text] [Related]

  • 33. Respiratory complications associated with IV zoledronic acid infusion in the treatment of postmenopausal osteoporosis.
    Taggart H, Cheng J, Archbold P.
    Osteoporos Int; 2010 Sep 30; 21(9):1621-2. PubMed ID: 19813042
    [No Abstract] [Full Text] [Related]

  • 34. [Ibandronate once a month].
    Polk B.
    Med Monatsschr Pharm; 2006 Jan 30; 29(1):36-7. PubMed ID: 16463553
    [No Abstract] [Full Text] [Related]

  • 35. Cost-effectiveness model of using zoledronic acid once a year versus current treatment strategies in postmenopausal osteoporosis.
    Fardellone P, Cortet B, Legrand E, Bresse X, Bisot-Locard S, Vigneron AM, Beresniak A.
    Joint Bone Spine; 2010 Jan 30; 77(1):53-7. PubMed ID: 20034831
    [Abstract] [Full Text] [Related]

  • 36. [Monthly tablet in postmenopausal osteoporosis].
    Krankenpfl J; 2005 Jan 30; 43(7-10):216. PubMed ID: 16515288
    [No Abstract] [Full Text] [Related]

  • 37. Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.
    Anastasilakis AD, Polyzos SA, Efstathiadou ZA, Savvidis M, Sakellariou GT, Papatheodorou A, Kokkoris P, Makras P.
    Metabolism; 2015 Oct 30; 64(10):1291-7. PubMed ID: 26198440
    [Abstract] [Full Text] [Related]

  • 38. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.
    Michaelson MD, Kaufman DS, Lee H, McGovern FJ, Kantoff PW, Fallon MA, Finkelstein JS, Smith MR.
    J Clin Oncol; 2007 Mar 20; 25(9):1038-42. PubMed ID: 17369566
    [Abstract] [Full Text] [Related]

  • 39. [Calcium pros and cons: long term use of bisphosphonates. Bisphosphonates should be used for postmenopausal osteoporosis for a long term].
    Soen S.
    Clin Calcium; 2011 Oct 20; 21(10):1543-6. PubMed ID: 21960242
    [Abstract] [Full Text] [Related]

  • 40. Going on a drug holiday?
    Bonnick SL.
    J Clin Densitom; 2011 Oct 20; 14(4):377-83. PubMed ID: 22051091
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.